PARSIPPANY, N.J.--(BUSINESS WIRE)--Jan. 15, 2013--
Pacira
Pharmaceuticals, Inc. (NASDAQ: PCRX) (the “Company”) today announced
that it proposes to offer $100 million of aggregate principal amount of
its convertible senior notes due 2019, subject to market conditions and
other factors. The notes are to be offered and sold only to qualified
institutional buyers pursuant to Rule 144A under the Securities Act of
1933, as amended. The notes will be the senior, unsecured obligations of
the Company and will accrue interest payable semiannually in arrears.
Upon conversion, holders will receive cash up to the principal amount of
the notes and, with respect to any excess conversion value, cash, shares
of the Company’s common stock, or a combination of cash and shares of
the Company’s common stock, at the Company’s option. The interest rate,
conversion rate, offering price and other terms will be determined at
the time of pricing of the offering. Pacira also expects to grant to the
initial purchasers a 30-day option to purchase up to an additional $10
million of aggregate principal amount of the notes on the same terms and
conditions, solely to cover sales in excess thereof, if any.
Pacira intends to use approximately $30.0 million of the net proceeds of
the offering to repay all amounts outstanding under, and to terminate,
its senior secured credit facility, and the remainder of the net
proceeds from the offering (including from any exercise by the initial
purchasers of their option to purchase additional notes) to fund the
continued commercialization of EXPAREL® and the development of
additional indications for EXPAREL and for general corporate purposes.
This announcement does not constitute an offer to sell, or the
solicitation of an offer to buy, any of these securities. Any offers of
the notes will be made only by means of a confidential offering
memorandum. The notes and the shares of the Company’s common stock
underlying these securities have not been and will not be registered
under the Securities Act of 1933, as amended, or the securities laws of
any other jurisdiction and may not be offered or sold in the United
States without registration or an applicable exemption from registration
requirements.
Forward Looking Statements
Certain of the statements made in this press release are forward
looking for purposes of the safe harbor provisions under The Private
Securities Litigation Reform Act of 1995, such as those, among others,
relating to our expectations regarding the completion of the proposed
notes offering. Actual results or developments may differ materially
from those projected or implied in these forward-looking statements.
Factors that may cause such a difference include, without limitation,
risks and uncertainties related to whether or not the Company will offer
the notes or consummate the offering, the anticipated terms of the notes
and the offering, the anticipated use of the proceeds of the offering,
and the impact of general economic, industry or political conditions in
the United States or internationally. There can be no assurance that we
will be able to complete the proposed notes offering on the anticipated
terms, or at all. Additional risks and uncertainties relating to Pacira
and our business are discussed in the "Risk Factors" section of our most
recent Annual Report on Form 10-K for the fiscal year ended December 31,
2011, our quarterly reports on Form 10-Q for the quarters ended June 30,
2012 and September 30, 2012 and in other filings that we periodically
make with the SEC. In addition, the forward-looking statements included
in this press release represent our views as of the date of this press
release. We anticipate that subsequent events and developments will
cause our views to change. However, while we may elect to update these
forward-looking statements at some point in the future, we specifically
disclaim any obligation to do so. These forward-looking statements
should not be relied upon as representing our views as of any date
subsequent to the date of this press release.
Information found on the Company’s website is not incorporated by
reference into this press release.
Source: Pacira Pharmaceuticals, Inc.
Pacira Pharmaceuticals, Inc.
James S. Scibetta, 973-254-3570
or
Pure
Communications, Inc.
Susan Heins, 864-286-9597
sjheins@purecommunicationsinc.com
